Skip to content
Sign in
StableHealthReported 2026-11-20 06:45

Malaria antibody L9LS protects infants but blunts R21 vaccine response

A Phase 1b trial in Mali found a single intramuscular dose of the monoclonal antibody L9LS safely provided 78% protective efficacy against malaria infection in infants aged 1-12 months during the six-month transmission season, but the antibody appeared to interfere with immune response to subsequent R21 vaccination, pausing plans for larger infant trials.

Why it matters. Infants too young for the R21 vaccine remain vulnerable to malaria; the trial shows L9LS can bridge that protection gap, but its use must be carefully timed relative to vaccination schedules, affecting future deployment strategies for…

01

Evidence

  • GGDELT Global Knowledge GraphMedia2026-11-20 06:45
    View source
  • MMedical XpressMedia2026-11-20 22:40
    View source